Illudin S inhibits p53-Mdm2 interaction for anticancer efficacy in colorectal cancer
Yoonsuk Lee1, Yun Young Lee2, Jinyoung Park3
1Department of Chemistry, Sungkyunkwan University, Suwon 16419, Republic of Korea; School of Pharmacy, Sungkyunkwan University, Suwon 16419, Republic of Korea.
Abstract:
The impairment of the p53 pathway was once regarded as inadequately druggable due to the specificity of the p53 structure, its flat surface lacking an ideal drug-binding site, and the difficulty in reinstating p53 function. However, renewed interest in p53-based therapies has emerged, with promising approaches targeting p53 and ongoing clinical trials investigating p53-based treatments across various cancers. Despite significant progress in p53-targeted therapies, challenges persist in identifying effective therapeutic targets within the p53 pathway. In this study, we implemented a molecular screening system to effectively discover p53 activator. As a result, illudin S was identified as a potential inhibitor of the p53-Mdm2 interaction. This compound is particularly intriguing due to its well-documented anti-cancer effects, despite the ambiguity surrounding its precise mechanism of action. Illudin S demonstrated a direct binding affinity to the Mdm2 binding site of p53 through hydrogen bonding, which enhanced the stability and transcriptional activity of p53. The inhibition of the p53-Mdm2 interaction by illudin S led to increased p53 expression. Moreover, this inhibition effectively induced apoptosis and cell cycle arrest in CT26 colorectal cancer cells. Administration of illudin S in a colorectal cancer mouse model resulted in prolonged survival and significant tumor growth inhibition. These findings elucidate the mechanism underlying the anti-cancer effects of illudin S, specifically through its targeting of the p53-Mdm2 interaction in colorectal cancer. Consequently, illudin S emerges as a promising candidate for the development of p53-targeted cancer therapies.
Insights
Illudin S activates the p53 pathway by inhibiting the p53-Mdm2 interaction. This novel approach shows promise for p53-targeted cancer therapies, demonstrating anti-cancer effects in colorectal cancer models.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Drug Discovery
Background:
- The p53 pathway, crucial for tumor suppression, has been historically challenging to target therapeutically due to the p53 protein's structure.
- Despite challenges, renewed interest in p53-based therapies is driving research into novel strategies for cancer treatment.
- Identifying effective targets within the p53 pathway remains a significant hurdle in developing successful p53-targeted therapies.
Purpose of the Study:
- To discover novel activators of the p53 pathway using a molecular screening system.
- To elucidate the mechanism of action of illudin S, a compound with known anti-cancer effects but an unclear mechanism.
- To evaluate illudin S as a potential therapeutic agent for colorectal cancer by targeting the p53-Mdm2 interaction.
Main Methods:
- A molecular screening system was employed to identify compounds that activate the p53 pathway.
- Illudin S was investigated for its interaction with p53 and its effect on the p53-Mdm2 complex.
- In vitro studies assessed illudin S's impact on p53 stability, transcriptional activity, apoptosis, and cell cycle arrest in colorectal cancer cells (CT26).
- In vivo studies evaluated the efficacy of illudin S in a colorectal cancer mouse model.
Main Results:
- Illudin S was identified as a novel inhibitor of the p53-Mdm2 interaction.
- Illudin S directly binds to the Mdm2 binding site on p53, enhancing p53 stability and transcriptional activity.
- Inhibition of the p53-Mdm2 interaction by illudin S increased p53 expression, induced apoptosis, and caused cell cycle arrest in CT26 cells.
- Administration of illudin S significantly inhibited tumor growth and prolonged survival in a colorectal cancer mouse model.
Conclusions:
- Illudin S effectively targets the p53-Mdm2 interaction, providing a mechanistic explanation for its anti-cancer effects in colorectal cancer.
- Illudin S demonstrates significant therapeutic potential as a p53 activator for p53-targeted cancer therapies.
- Further development of illudin S could lead to novel treatment strategies for various cancers.
More Related Videos
Related Concept Videos
02:23Abnormal Proliferation
02:34Inhibition of Cdk Activity
01:15Drugs that Stabilize Microtubules
01:23Negative Regulator Molecules
02:37DNA Damage can Stall the Cell Cycle
01:31The Intrinsic Apoptotic Pathway